The Push for Generics Challenges Manufacturers

July 2, 2003

Jill Wechsler

Jill Wechsler

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Pharmaceutical Technology, Pharmaceutical Technology-07-02-2003, Volume 27, Issue 7

Biotech firms face new issues as FDA weighs policies to streamline generic-drug approvals and reduce patent disputes.

Related Content:

Quality SystemsRegulatory WatchGeneric DrugsDosage FormsPharmaceutical Technology-07-02-2003

FDA Recommends Pausing Use of J&J COVID-19 Vaccine After Reports of Blood Clots

FDA Inspectors Cited Critical Problems at Emergent Facility

Balancing the Art and Science of Topical Drug Formulation